Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zavegepant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL known ✓ | Q16602 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CALCA | P06881 | 16/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zavegepant SCHEMBL142472 | 1.00 | CALCRL (1.00) | CALCRLCYP3A4CALCA | |
| Zavegepant SCHEMBL23748834 | 1.00 | CALCRL (1.00) | CALCRLCYP3A4CALCA | |
| Zavegepant SCHEMBL107428 | 1.00 | CALCRL (1.00) | CALCRLCYP3A4CALCA | |
| Zavegepant SCHEMBL29360253 | 1.00 | CALCRL (1.00) | CALCRLCYP3A4CALCA | |
| Zavegepant SCHEMBL29182146 | 0.99 | CALCRL (0.99) | CALCRLCYP3A4CALCA | |
| Zavegepant SCHEMBL29918668 | 0.99 | CALCRL (0.99) | CALCRLCYP3A4CALCA | |
| SCHEMBL30763651 | 0.97 | CALCRL (0.95) | CALCRLCYP3A4CALCA | |
| SCHEMBL29161729 | 0.97 | CALCRL (0.95) | CALCRLCYP3A4CALCA | |
| SCHEMBL29161731 | 0.97 | CALCRL (0.95) | CALCRLCYP3A4CALCA | |
| SCHEMBL178848 | 0.93 | CALCRL (0.88) | CALCRLCYP3A4CALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4504717-A1 | SOLID STATE FORMS OF ZAVEGEPANT HYDROCHLORIDE AND PROCESS FOR PREPARATION THEREOF | Teva Czech Industries s.r.o (CZ) | 2025-02-12 | — | — | EP | disclosed |
| US-20240199578-A1 | SOLID STATE FORMS OF ZAVEGEPANT AND PROCESS FOR PREPARATION THEREOF | TEVA CZECH INDUSTRIES S.R.O | 2024-06-20 | — | — | US | disclosed |
| WO-2024100599-A1 | SOLID STATE FORMS OF ZAVEGEPANT HYDROCHLORIDE AND PROCESS FOR PREPARATION THEREOF | TEVA CZECH INDUSTRIES S.R.O. (CZ) | 2024-05-16 | — | — | WO | disclosed |
| EP-4320113-A1 | SOLID STATE FORMS OF ZAVEGEPANT AND PROCESS FOR PREPARATION THEREOF | Teva Czech Industries s.r.o. (CZ) | 2024-02-14 | — | — | EP | disclosed |
| WO-2023034466-A1 | CGRP ANTAGONISTS FOR TREATING PSORIASIS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-03-09 | — | — | WO | disclosed |
| WO-2022217008-A1 | SOLID STATE FORMS OF ZAVEGEPANT AND PROCESS FOR PREPARATION THEREOF | TEVA CZECH INDUSTRIES S.R.O (CZ) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199578-A1 | SOLID STATE FORMS OF ZAVEGEPANT AND PROCESS FOR PREPARATION THEREOF | PIGT, SOST, VKORC1 | CALCRL 3819/4885CYP3A4 20/4885CALCA 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.